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Objectives: Mitochondrial abnormalities have been described in cardiac
tissue of patients with heart failure. These changes may result from chronic
hypoxia. Our goal was to determine whether mitochondrial functional
capacity can be improved in patients with heart failure by means of
long-term left ventricular assist device therapy, which improves myocardial
oxygen supply by decreasing myocardial work. Methods: Mitochondria were
isolated from myocardial tissue obtained from 13 patients with heart
failure without a left ventricular assist device (HF group) and seven
patients with heart failure treated with a left ventricular assist device
(LVAD-HF group). Mitochondrial respiratory rates (State 2, State 3, and
State 4) were measured by means of polarographic techniques with reduced
nicotinamide adenine dinucleotide–dependent (pyruvate/malate, a-keto-
glutarate, glutamate) and –independent (succinate) substrates. The respi-
ratory control index of Chance (State 3/State 4) and Lardy (State 3/State 2)
and phosphorus to oxygen ratios were determined. Results: The respiratory
control index of Chance was higher in LVAD-HF than in HF when using
NADH-dependent substrates pyruvate/malate and a-ketoglutarate (pyru-
vate/malate HF: 4.9 6 1.0; LVAD-HF: 6.5 6 1.5; a-ketoglutarate HF: 8.5 6
2.4; LVAD-HF: 11.8 6 2.9; both p 5 0.04). Similarly, the respiratory control
index of Lardy was greater in the LVAD-HF than the HF group when
a-ketoglutarate and glutamate were used as substrates (a-ketoglutarate
HF: 7.8 6 1.7; LVAD-HF: 9.9 6 1.5; glutamate HF: 7.6 6 2.2; LVAD-HF:
10.7 6 2.1; both p 5 0.04). The phosphorus to oxygen ratio was comparable
for both groups using all substrates. No change in mitochondrial respira-
tion was observed after left ventricular assist device therapy with the
NADH-independent substrate, succinate. Conclusion: Cardiomyocyte mito-
chondrial function is improved by long-term therapy with a left ventricular
assist device. This improvement suggests that cardiomyocyte metabolic
dysfunction in heart failure may be reversed with left ventricular assist
device support. (J Thorac Cardiovasc Surg 1998;116:344-9)
Mitochondria are key intracellular organelles thatconvert oxygen, glucose, free fatty acids, and
amino acids into biologically usable energy in the
form of adenosine triphosphate (ATP). Control of
mitochondrial respiration influences the energy out-
put of the cell and subsequently the organ.
Structural and functional cardiomyocyte mito-
chondrial abnormalities have been described in an-
imal models of heart failure (HF) and in human
HF.1-7 Electron micrographs from a canine micro-
embolization model of HF demonstrated structural
defects including decreased mitochondria size with
matrix depletion and membrane disruption.6 Simi-
larly, electron micrographs from hibernating human
myocardium demonstrate changes in mitochondrial
structure, possibly related to damage from free
oxygen radicals. Sabbah and associates6 reported
extremely low respiratory control indexes (RCIs) in
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both animal and human HF when using saponified
skinned myocytes. Reduced mitochondrial function
has been shown in some animal models of HF8-10
and in human cardiac tissue obtained at the time of
transplantation.11
Although both functional and structural myocar-
dial mitochondrial defects may contribute to HF,
the reversibility of either has not been determined in
a clinical population. Implantation of a left ventric-
ular assist device (LVAD) in end-stage HF permits
extreme unloading of the left ventricle, thus de-
creasing myocardial oxygen consumption. Pro-
longed mechanical unloading in patients with
LVADs results in a reversal of neurohormonal
stimulation and in a normalization of the compro-
mised pressure/volume relationship in explanted
hearts.12-14 Histologic improvement, such as the
reduction of cellular edema, has also been shown in
endomyocardial biopsy tissues after unloading.15
However, the effects of prolonged mechanical un-
loading on myocardial metabolism or mitochondrial
function in these patients has not been investigated.
The purpose of the present study was to deter-
mine whether cardiomyocyte mitochondrial func-
tion is improved after long-term LVAD therapy.
Mitochondrial respiratory function was evaluated by
means of routine polarographic techniques.16, 17
Methods
Patient population. Twenty patients were studied.
Eight patients with end-stage HF had mitochondria iso-
lated from the explanted organ at the time of transplan-
tation and five patients at the time of LVAD implantation.
These 13 patients with end-stage HF comprised the HF
group. Seven patients with HF had mitochondria isolated
at the time of explantation after having been on LVAD
support for 185 6 81 days (LVAD-HF; range 35 to 357
days). These seven patients formed the LVAD-HF group.
The clinical characteristics of the two groups are pre-
sented in Table I. Patient age averaged 42 6 14 years; the
majority of patients had dilated cardiomyopathy; ejection
fraction averaged 17% (HF: 16 6 4; LVAD-HF: 17 6 5).
This study was approved by our institutional review board
and consent was obtained from each patient.
Isolation of mitochondria. Approximately 1 gm of myo-
cardium from explanted hearts (n 5 15) or from the left
ventricular apex (n 5 5) was obtained. For the explanted
hearts, usually the left ventricular free wall (or other parts
of the myocardium without scar tissue) was used. Right
ventricular free wall samples were also obtained in five of
the seven patients who had LVADs implanted before
transplantation.
Mitochondria were isolated by differential centrifuga-
tion according to Kondrashova and Doliba.17 Heart tissue
was chilled, weighed, and homogenized in a glass Potter-
Elvehjein homogenator (Ann Arbor, Mich.) with a motor-
driven Teflon pestle. The homogenization buffer con-
tained sucrose 300 mmol/L, HEPES 10 mmol/L,
ethylenediaminetetraacetic acid (EDTA) 1 mmol/L, and
bovine serum albumin 0.25% (pH 5 7.4). After initial
centrifugation (7 minutes at 480g), the pellet, containing
nuclei and other cellular debris, was discarded. The
supernatant was centrifuged at 10,000g for 10 minutes to
obtain the mitochondrial fraction.
Measurement of mitochondrial oxidative states. Mito-
chondrial respiratory function (State 2: oxidation with
substrate only, no adenosine diphosphate [ADP]; State 3:
oxygen consumption in nanoatoms stimulated by ADP;
State 4: oxygen consumption in the absence of ADP; RCI;
ratio of State 3 to State 4 [Chance]; State 3 to State 2
[Lardy]; and ADP/O: ratio between the nanomoles of
ADP phosphorylated to ATP and nanoatoms of oxygen
consumed) was measured by means of polarographic
methods.18 The incubation buffer contained sucrose 250
mmol/L, KCl 40 mmol/L, KH2PO4 l mmol/L, EDTA 0.5
mmol/L, and HEPES 5 mmol/L (pH 7.4). Four substrates
were used: a-ketoglutarate 1 mmol/L; pyruvate plus
malate 1 mmol/L; glutamate 1 mmol/L; and succinate 1
mmol/L. The number of substrates used depended on the
availability of adequate cardiac tissue and thus mitochondria.
Fig. 1. Comparison of the RCIs of Chance and Lardy and
P/O ratio using a-ketoglutarate as the substrate in patients
with coronary artery disease (CAD) and idiopathic dilated
cardiomyopathy (IDC).
Table I. Clinical characteristics
All patients HF LVAD-HF
No. 20 13 7
Age (yr) 42 6 14 43 6 14 41 6 14
Gender
Women 7 4 3
Men 13 9 4
Etiology
Dilated cardiomyopathy 14 10 4
Coronary artery disease 6 3 3
Ejection fraction (%) 17 6 5 16 6 4 17 6 5
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Determination of mitochondrial protein. Mitochon-
drial protein was determined by means of the Biuret
technique18 and used to normalize oxidative function
data.
Statistical analysis. All results are expressed as mean 6
standard deviation. Comparisons between mean values were
performed by the use of a paired Student’s t test.
Results
Mitochondrial function in all patients. The phos-
phorus to oxygen (P/O) ratio for all NADH-depen-
dent substrates* averaged 3 and for the NADH-
independent substrate, succinate, averaged 2. When
mitochondrial data were divided into two subgroups
on the basis of the cause of heart failure (coronary
artery disease and idiopathic dilated cardiomyopa-
thy), the RCIs of Chance and Lardy were not
significantly different. The data using the rate-limit-
ing substrate for the Krebs cycle, a-ketoglutarate,
are shown in Fig. 1.
Comparison of mitochondrial function of pa-
tients in the HF and LVAD-HF groups. Data for
HF and LVAD-HF groups are presented in Table
II. Statistically significant increases in the RCIs of
Chance and Lardy were observed in the LVAD-HF
group compared with the end-stage HF group using
a-ketoglutarate. For the other NADH-dependent
substrates (i.e., pyruvate/malate and glutamate) the
RCIs of either Chance or Lardy were higher in
the LVAD-HF group. In contrast, no change in RCI
was observed in the NADH-independent/FAD-de-
pendent substrate* succinate with LVAD therapy.
The P/O ratios using NADH-dependent or NADH-
independent substrates were similar for both groups.
Polarographic tracings from a patient in the HF
group and in the LVAD-HF group are shown in Fig.
2. The bold tracing represents the LVAD-HF pa-
tient and the thin line demonstrates a typical tracing
from a patient with end-stage HF. The slopes of
States 2 and 4 are reduced in the LVAD-HF patient
relative to the HF subject. This results in higher
respiratory control. State 3 is comparable in both
HF and LVAD-HF patients.
Comparison of respiratory control in the right
and left ventricles of LVAD-HF patients. In five of
the LVAD-HF patients, mitochondria were isolated
from both the unsupported right ventricle and the
supported left ventricle (Table III). The RCI was
similar for both ventricles. This may suggest global
improvement in mitochondrial metabolism in both
right and left ventricles in the patients supported by
LVAD. However, without comparison with mito-
chondria from the right ventricle of HF patients
without LVAD, this cannot be substantiated.
Discussion
This study demonstrates an improvement of car-
diomyocyte mitochondrial function in patients after
long-term therapy with LVADs in both right and left
ventricular tissue. It also demonstrates that some
degree of respiratory control is maintained in hu-
* NADH 5 Reduced nicotinamide adenine dinucleotide. *FAD 5 Flavin adenine dinucleotide.
Table II. Comparison of end-stage HF and LVAD-HF groups
Substrate Pyruvate/malate a-Ketoglutarate Glutamate Succinate
HF
No. 13 12 11 11
State 2* 10.3 6 6.5 7.6 6 3.8 7.9 6 3.6 29.6 6 18.0
State 3* 49.7 6 30.4 53.4 6 20.7 56.5 6 21.2 74 6 36
State 4* 10.2 6 5.5 7.3 6 3.9 7.1 6 3.1 21.8 6 11.2
RCI Chance 4.9 6 1.0 8.5 6 2.4 8.1 6 2.1 3.6 6 1.1
RCI Lardy 5.2 6 1.3 7.8 6 1.7 7.6 6 2.2 3.2 6 1.1
P/O 3.3 6 0.3 3.2 6 0.4 3.3 6 0.7 2.3 6 0.4
LVAD-HF
No. 7 7 6 6
State 2* 7.5 6 4.4 5.5 6 3 4.2 6 2.4 12.2 6 6.4
State 3* 45.8 6 23 51.5 6 25 40.4 6 19.6 38.6 6 27
State 4* 7.4 6 4.4 5.1 6 3 4.0 6 2.1 10.7 6 6.4
RCI Chance 6.5 6 1.5† 11.8 6 2.9† 10.7 6 2.7 3.3 6 0.7
RCI Lardy 6.4 6 1.5 9.9 6 1.5† 10.7 6 2.1† 2.9 6 0.8
P/O 3.3 6 0.3 3.1 6 0.2 3.0 6 0.2 2.3 6 0.5
*Nanoatoms of oxygen per milligram per minute
†p , 0.05, HF versus LVAD-HF.
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man heart mitochondria after the development of
HF.
Mitochondrial function in HF. Whether a bioen-
ergetic defect characterized by an impairment of oxi-
dative phosphorylation is present in the failing human
heart is unclear. Prior observations in experimental
animal models of HF have demonstrated conflicting
results,5-9, 19, 20 with some investigators demonstrating
normal RCIs.20 In animals in which aortic banding was
used to produce HF, the RCI was lower in animals
with HF than in control animals.19 In rabbits with
cardiac hypertrophy produced by an aortic Ameroid
constrictor, the RCI was decreased in the failing but
not in the hypertrophied hearts.10 In these animals,
calcium uptake by the mitochondria was significantly
decreased in the failing hearts.
Few studies have examined human myocardial
mitochondrial function. In 1966, Chidsey and asso-
ciates21 obtained papillary muscle from patients
with left ventricular dysfunction who were undergo-
ing valve replacement. They demonstrated a pre-
served P/O ratio and similar RCIs to those of
mitochondria isolated from normal experimental
animals and from right ventricular tissue from two
patients with tetralogy of Fallot. In 1971, Linden-
mayer and colleagues11 recorded the RCI from
cardiac tissue from heart transplant recipients with
coronary artery disease using both NADH-depen-
dent and -independent substrates. They reported a
reduced rate of oxygen consumption in the presence
of ADP in mitochondria from the failing recipient
hearts. More recently, Sabbah and coworkers,6 using
saponified myocytes from heart transplant recipi-
ents, reported a loss of respiratory control in the
failing heart. However, the technique of saponiza-
tion may have damaged mitochondrial membranes
and contributed to these findings.
In our study, the P/O ratio was normal, consistent
with the findings of Lindenmayer,11 Chidsey,21 and
their associates. The RCI tended to be lower than
that reported by Lindenmayer and coworkers11 and
similar to those reported by Chidsey and cowork-
ers.21 However, whether the RCI measured in these
studies represents a normal rate of respiration in
human beings remains unclear, because no histori-
cal controls are available for comparison owing to
the difficulty in obtaining normal human heart tissue.
In our study, the RCI and P/O ratios in mitochon-
dria of patients with coronary artery disease and
dilated cardiomyopathy were similar, suggesting
that the end result of these different pathophysio-
logic processes is similar.
Improvement in respiratory control with LVAD
therapy. The most significant finding was an im-
provement in the RCI observed after LVAD sup-
port using NADH-dependent Krebs cycle sub-
strates. The improvement in respiratory control
resulted primarily from shifts of the slopes of State
2 and State 4. The lack of shift in the slope of State
3 suggests that electron chain transport is unaffected
and appears to be normal. The rates of State 2 and
4 respiration are influenced by free fatty acid accu-
mulation and calcium overload, both of which affect
membrane potential. These changes decrease the
coupling between the oxidation of substrates in the
Krebs cycle and ATP synthesis in the respiratory
chain. Thus one possible mechanism for the change
in the rate of State 4 respiration is an alteration in
mitochondrial calcium levels. Cytoplasmic calcium
overload could result in increased mitochondrial
calcium levels. In the Syrian hamster, the RCI
declines as the cardiomyopathic process progresses
and is inversely related to the ratio of intracellular
calcium and magnesium.22 Thus respiratory control
diminishes as cytosolic calcium overload occurs. In
this hamster model, diminished respiratory control
results from altered State 4 respiration, as State 3
respiration and P/O ratios remain unchanged.23
Whether a similar effect occurs in human HF is
unknown. Future studies on isolated mitochondria
incorporating calcium measurements may be helpful
in clarifying the role of calcium.
Other potential mechanisms for improved mito-
chondrial function after LVAD therapy may simply
be due to structural effects, that is, a reduction in
myocyte stretch. Echocardiograms in the patients
supported by an LVAD demonstrated markedly
Fig. 2. Oxygen electrode tracing in a patient before and
after LVAD support. Oxygen concentration expressed as
percent. CHF, Congestive heart failure.
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diminished left ventricular size.14 Pathology speci-
mens from patients after explantation have also
demonstrated reduction in myocyte area.12 Alter-
nately, increased oxygen delivery may be a primary
factor for the observed changes either by decreasing
the diffusion distance as a consequence of myocyte
atrophy or increasing supply by virtue of the de-
creased cellular workload. Decrease in catechol-
amine stimulation with LVAD support is another
potential mechanism for the observed improvement
in mitochondrial function.12, 13, 24
It is not surprising that no change in mitochon-
drial respiration was observed when an NADH
independent/FAD-dependent substrate (succinate)
was used, because this represents a less efficient use
of oxygen. This is in contrast to the NADH-depen-
dent substrates (pyruvate/malate, glutamate), which
demonstrate more efficient oxygen use for ATP
demonstrated by an increase in RCI and decrease in
State 4 respiration in the LVAD-HF group.
Whether the improvement in mitochondrial
function after LVAD support translates into im-
provement in mechanical function cannot be an-
swered by this study. Ejection fractions were
similar between the two groups at the time of
LVAD insertion; however, cellular and mechani-
cal function were not concordantly measured after
a period of LVAD support. Recently, using an
isolated myocyte preparation, Dipla and cowork-
ers25 described the contractile properties of myo-
cytes isolated from five patients with LVAD sup-
port compared with myocytes from 19 explanted
failing hearts. The fractional shortening, time to
peak contraction, time to 50% relaxation, and
fractional shortening after exposure to isoproter-
enol were all significantly improved in the patients
supported with an LVAD. These findings would
suggest that mechanical function should improve
with LVAD support.
Different patients had different levels of inotropic
support that will affect myocardial oxygen consump-
tion. Only three of the HF patients were not receiv-
ing parenteral inotropic support at the time of
transplantation. None of the LVAD patients were
receiving parenteral inotropic agents. LVAD sup-
port should decrease myocardial oxygen consump-
tion by decreasing myocardial work. However, the
measurement of the RCI describes the efficiency of
mitochondrial metabolism independent of load.
Past evidence from animal and human studies sug-
gest that inotropic agents improve rather than
worsen mitochondrial function. Unverferth and as-
sociates26 described a morphologic improvement in
mitochondria from patients with HF after inotropic
support. Quantitative ultrastructural analysis of
electron micrographs from biopsy tissue of patients
before and after 72-hour infusion of dobutamine
showed an increase in cristae-to-matrix ratio and
mitochondrial size in comparison with samples de-
rived from patients who received only bedrest.
These morphologic improvements do not necessar-
ily mean that there is a coexistent functional im-
provement. However, animal studies would support
both morphologic and functional improvement after
treatment with inotropic agents. The effect of dopa-
mine, dobutamine, and amrinone on mitochondrial
function in a canine infarct model of cardiogenic
shock was studied by Mukae and colleagues.27 All of
the inotropic agents were shown to significantly
improve the RCI in animals receiving succinate or
glutamic acid/malic acid compared with animals
receiving only saline solution. Morphologic deterio-
ration of mitochondria with swelling and fusion was
observed only in the saline-treated animals. Other
animal studies using different models have also
demonstrated improvement of mitochondrial func-
tion with inotropic support.28, 29 It is therefore un-
likely that our findings represent an epiphenomena.
If all the patients with end-stage HF (LVAD, non-
LVAD) had the same positive inotropic treatment,
it is likely that the difference in mitochondrial
efficiency (estimated by the RCI) between the two
groups would have been exaggerated.
Study limitations. The biochemical techniques
used in this study to measure mitochondrial respi-
ration are well established. The accuracy of our
protein determinations may be limited by small
amounts of tissue. As the tissue was processed im-
mediately, potential damage from prolonged inade-
quate tissue preservation was not a factor. This study is
also limited by the lack of measurements from normal
human myocardium. Biopsy specimens do not provide
adequate tissue to isolate mitochondria.
Table III. Comparison of mitochondrial function in
left and right ventricles of LVAD-HF patients
(n 5 5) using a-ketoglutarate
Right ventricle Left ventricle
State 2* 8.5 6 4 11.9 6 3.0
State 3* 64 6 21 66 6 15
State 4* 10.8 6 2.7 11.2 6 2.7
P/O ratio 3.1 6 0.1 3.2 6 0.2
*Nanoatoms of oxygen per milligram per minute.
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Clinical limitations of this study include the small
sample size. Longitudinal rather than cross-sec-
tional analysis would have been preferable. Owing
to the prolonged LVAD support in many of these
patients, longitudinal analysis was not possible. Ad-
ditional information including measurement of mi-
tochondrial enzymes, free fatty acids, pH, and ultra-
structural assessment of the mitochondria would
have helped to elucidate the mechanism of the
improved mitochondrial function. Unfortunately,
these measurements were not obtained.
Conclusion
In conclusion, long-term LVAD support in pa-
tients with HF reduces cardiovascular load and
improves myocardial mitochondrial function. Pa-
tients have more efficient energy production after
LVAD support. This improvement in myocardial
mitochondrial function has important clinical impli-
cations, because it suggests some reversibility of
cardiac metabolic dysfunction with LVAD support.
R E F E R E N C E S
1. Williams RS. Cardiac involvement in mitochondrial diseases,
and vice versa. Circulation 1995;91:1266-8.
2. Anan R, Nakagawa M, Miyata M, et al. Cardiac involvement
in mitochondrial diseases: a study on 17 patients with docu-
mented mitochondrial DNA defects. Circulation 1995;91:
955-61.
3. Corral Debrinski M, Stepien G, Shoffner J, Lott M, Kanter K,
Wallace D. Hypoxemia is associated with mitochondrial
DNA damage and gene induction: implications for cardiac
disease. JAMA 1991;266:1812-8.
4. Marin-Garcia J, Goldenthal M. Cardiomyopathy and abnormal
mitochondrial function. Cardiovasc Res 1994;28:456-63.
5. Ozawa T. Mitochondrial cardiomyopathy. Herz 1994;19:105-18.
6. Sabbah H, Sharov V, Riddle J, Kono T, Lesch M, Goldstein
S. Mitochondrial abnormalities in myocardium of dogs with
chronic heart failure. J Mol Cell Cardiol 1992;24:1333-67.
7. Shoffner J, Wallace D. Heart disease and mitochondrial
DNA mutations. Heart Dis Stroke 1992:1:235-41.
8. Proscheck L, Jasmin G. Hereditary polymyopathy and car-
diomyopathy in the Syrian hamster. II. Development of heart
necrotic changes in relation to defective mitochondrial func-
tion. Muscle Nerve 1982;5:26-32.
9. Lindenmayer GE, Sordahl LA, Schwartz A. Reevaluation of
oxidative phosphorylation in cardiac mitochondria from nor-
mal animals and animals in heart failure. Circ Res 1968;23:
439-50.
10. Sordahl LA, McCollum WB, Wood WG, Schwartz A. Mito-
chondria and sarcoplasmic reticular function cardiac hyper-
trophy and failure. Am J Physiol 1973;224:497-502.
11. Lindenmayer GE, Sordahl LA, Harigaya S, Allen JC, Besch HR
Jr, Schwartz A. Some biochemical studies on subcellular systems
isolated from fresh recipient human cardiac tissue obtained
during transplantation. Am J Cardiol 1971;27:277-83.
12. Levin H, Chen J, Oz M, et al. Potential of left ventricular
assist devices as outpatient therapy while awaiting transplan-
tation. Ann Thorac Surg 1994;58:1515-20.
13. Estrada-Quintero T, Uretsky B, Murali S, Griffith B, Kormos
R. Neurohormonal activation and exercise function in pa-
tients with severe heart failure and patients with left ventric-
ular assist system. Chest 1995;107:1499-503.
14. Levin H, Oz M, Chen J, Packer M, Rose E, Burkhoff D.
Reversal of chronic ventricular dilation in patients with end
stage cardiomyopathy by prolonged mechanical unloading.
Circulation 1995;91:2717-20.
15. Fisher P, DeRosa C, Choudri A, Oz M. Mechanical assist
device placement in end stage heart failure results in signif-
icant ventricular remodeling [abstract]. J Heart Lung Trans-
plant 1997;16:81A.
16. Chance B, Williams GR. The respiratory chain and oxidative
phosphorylation. Adv Enzymol 1956;17:65-134.
17. Kondrashova M, Doliba N. Polarographic observation of
substrate-level phosphorylation and its stimulation by acetyl-
choline. FEBS Lett 1984;243:153-5.
18. Gornall A, Bardawill C, David M. J Biol Chem 1949;177:
751-5.
19. Sobel BE, Spann JF, Pool PE, Sonnenblick EH, Braunwald
D. Normal oxidative phosphorylation in mitochondria from
the failing heart. Circ Res 1967;21:355.
20. Cooper G IV, Puga F, Zujko KT, Harrison CE, Coleman HN
III. Normal myocardial function and energetics in volume-
overloaded hypertrophy in the cat. Circ Res 1973;32:140.
21. Chidsey C, Weinbach E, Pool P, Morrow A. Biochemical
studies of energy production in the failing human heart.
J Clin Invest 1966;45:40-50.
22. Jasmin G, Proschek L. Calcium and myocardial cell inju-
ry—an appraisal in the cardiomyopathic hamster. Can
J Physiol Pharmacol 1984; 61:891-8.
23. Doliba NM. Calcium as the mediator of stress induced
dysfunction in cardiomyopathic hamster hearts? Exp Biol
April 1996, Washington DC. Abstract.
24. Khan T, Levin H, Oz M, Katz S. Delayed reversal of impaired
metabolic vasodilation in patients with end stage heart failure
during long term circulatory support with a left ventricular
assist device. J Heart Lung Transplant 1997;16:449-53.
25. Dipla K, Mattiello J, Jeevanandum V, Paolone A, Margulies
K, Houser S. Improved myocyte function following mechan-
ical support of the left ventricle in humans with severe heart
failure [abstract]. Circulation 1997;96:298A.
26. Unverferth D, Leier C, Magorien R, Croskery R, Svirbely J,
Kolibash A, et al. Improvement of human myocardial mito-
chondria after dobutamine: a quantitative ultrastructural
study. J Pharmacol Exp Ther 1980;215:527-32.
27. Mukae S, Yanagishita T, Geshi E, Umetsu K, Tomita M, Itoh
S, et al. The effects of dopamine, dobutamine, and amrinone
on mitochondrial function in cardiogenic shock. Jpn Heart J
1997;38:515-29.
28. Das A, Harris D. Control of mitochondrial ATP synthase in
heart cells: inactive to active transitions caused by beating or
positive inotropic agents. Cardiovasc Res 1990;24:411-17.
29. McCormack J, Denton R. The role of calcium in the regula-
tion of intramitochondrial energy production in heart.
Biomed Biochim Acta 1987;46:S487-92.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 116, Number 2
Lee et al. 3 4 9
